CBT-001

N/A

Report date: 2023/09/05 20:09:53
NME

Base Information

Drug NameCBT-001
Drug Alias NameCBT-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor antagonistsPlatelet-derived growth factor receptor inhibitorsFibroblast growth factor receptors antagonists
TargetsVascular endothelial growth factor receptorPlatelet-derived growth factor receptorFibroblast growth factor receptors
Therapy Area/IndicationsHyperemiaPterygium
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCloudbreak Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesSanten Pharmaceutical Co LtdCloudbreak Therapeutics LlcCloudbreak Biomedical Technology (Guangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsHyperemiaPterygium
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A